Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Urogynecology Journal
Published in: International Urogynecology Journal 6/2017

Open Access 01-06-2017 | Original Article

Urinary retention in female OAB after intravesical Botox injection: who is really at risk?

Authors: Pawel Miotla, Rufus Cartwright, Katarzyna Skorupska, Michal Bogusiewicz, Ewa Markut-Miotla, Konrad Futyma, Tomasz Rechberger

Published in: International Urogynecology Journal | Issue 6/2017

Login to get access

Abstract

Introduction and hypothesis

Intravesical onabotulinumtoxinA (Botox) injections are effective for the treatment of idiopathic overactive bladder (OAB) symptoms. The aim of our study was to assess the predisposing factors for urinary retention in women with OAB after intravesical Botox injection.

Methods

All participants were women of European descent with idiopathic OAB. OnabotulinumtoxinA (100 U) was administered in 20 intra-detrusor injections. Analysis was performed based on the results of safety assessments made during follow-up (FU) visits on weeks 2, 4 and 12, in 208 women who were treated with Botox injections for refractory OAB and who completed all FU visits.

Results

Women who required clean intermittent self-catheterisation (CISC) and those with post-void residual (PVR) greater than 200 ml were older in comparison with patients with PVR between 50 and 200 ml. Patients who required CISC were also characterised by higher parity and particularly by a higher number of vaginal deliveries. Other factors such as body mass index or comorbidities did not significantly influence PVR and the risk of CISC.

Conclusions

Elderly and/or multiparous women are at increased risk of urinary retention after intravesical 100-U Botox injections. The risk of new onset urine retention in our study has completely disappeared 2 weeks after Botox injections. Based on our results of the way in which the PVRs have changed over time, we can conclude that OAB patients should be optimally assessed during the first 2 weeks after Botox injections.
Literature
1.
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26.CrossRefPubMed
2.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–6.CrossRefPubMed
3.
Wu JM, Matthews CA, Conover MM, Pate V, Jonsson Funk M. Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol. 2014;123:1201–6.CrossRefPubMedPubMedCentral
4.
Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63.CrossRefPubMed
5.
6.
Rovner E. Chapter 6: Practical aspects of administration of onabotulinumtoxinA. Neurourol Urodyn. 2014;33 Suppl 3:S32–7.CrossRefPubMed
7.
Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, et al. Durable efficacy and safety of long-term OnabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5 year study. J Urol. 2016. doi:10.​1016/​j.​juro.​2016.​03.​146.
8.
Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189:2186–93.CrossRefPubMed
9.
Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249–56.CrossRefPubMed
10.
Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184:2416–22.CrossRefPubMed
11.
Osborn DJ, Kaufman MR, Mock S, Guan MJ, Dmochowski RR, Reynolds WS. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn. 2015;34:675–8.CrossRefPubMed
12.
Bump RC, Mattiasson A, Bø K, Brubaker LP, DeLancey JO, Klarskov P, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996;175:10–7.CrossRefPubMed
13.
Hashim H, Beusterien K, Bridges JF, Amos K, Cardozo L. Patient preferences for treating refractory overactive bladder in the UK. Int Urol Nephrol. 2015;47:1619–27.CrossRefPubMed
14.
Balchandra P, Rogerson L. Women’s perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment. Int Urogynecol J. 2014;25:1059–64.CrossRefPubMed
15.
Fitzgerald MP, Jaffar J, Brubaker L. Risk factors for an elevated postvoid residual urine volume in women with symptoms of urinary urgency, frequency and urge incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12:237–9.CrossRefPubMed
16.
Milleman M, Langenstroer P, Guralnick ML. Post-void residual urine volume in women with overactive bladder symptoms. J Urol. 2004;2004(172):1911–4.CrossRef
17.
US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research. Clinical practice guidelines: urinary incontinence in adults. Washington DC: US Department of Health and Human Services; 1992.
18.
Kobashi K. Evaluation and management of women with urinary incontinence and pelvic prolapse. In: Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016. p. 1697–709.
19.
Gehrich A, Stany MP, Fischer JR, Buller J, Zahn CM. Establishing a mean postvoid residual volume in asymptomatic perimenopausal and postmenopausal women. Obstet Gynecol. 2007;110:827–32.CrossRefPubMed
20.
Davis NF, Burke JP, Redmond EJ, Elamin S, Brady CM, Flood HD. Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events. Int Urogynecol J. 2015;26:313–9.CrossRefPubMed
21.
Marcelissen TA, Rahnama’i MS, Snijkers A, Schurch B, De Vries P. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. World J Urol. 2016. doi:10.​1007/​s00345-016-1862-y.PubMed
22.
Miotla P, Cartwright R, Futyma K, Bogusiewicz M, Skorupska K, Winkler I, et al. Can botox improve night-time overactive bladder symptoms in women? Neurourol Urodyn. 2016. doi:10.​1002/​nau.​22983.
23.
Wang CC, Liao CH, Kuo HC. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity. Neurourol Urodyn. 2014;33:1235–9.CrossRefPubMed
24.
Jiang YH, Ong HL, Kuo HC. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome—a real-life practice of 290 cases in a single center. Neurourol Urodyn. 2015. doi:10.​1002/​nau.​22892.
25.
Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013;189:1804–10.CrossRefPubMed
26.
Milsom I, Altman D, Cartwright R, Lapitan MC, Nelson R, Sillén U, Tikkanen K. Epidemiology of Urinary Incontinence (UI) and other Lower Urinary Tract Symptoms (LUTS), Pelvic Organ Prolapse (POP) and Anal (AI) Incontinence. In: Abrams P, Cardozo L, Kouhry S, Wein A, editors. Incontinence, 5th edn. Paris: Health Publications Ltd; 2013. p. 15–107.
Metadata
Title
Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
Authors
Pawel Miotla
Rufus Cartwright
Katarzyna Skorupska
Michal Bogusiewicz
Ewa Markut-Miotla
Konrad Futyma
Tomasz Rechberger
Publication date
01-06-2017
Publisher
Springer London
Published in
International Urogynecology Journal / Issue 6/2017
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-016-3212-4

Other articles of this Issue 6/2017

International Urogynecology Journal 6/2017 Go to the issue

Original Article

A validated translation of a survey for measuring incontinence knowledge in Chinese-speaking American immigrants

Original Article

Robot-assisted vesicovaginal fistula repair: a safe and feasible technique

Original Article

Laparoscopic sacrocolpopexy: operative times and efficiency in a high-volume female pelvic medicine and laparoscopic surgery practice

Clinical Opinion

In the footsteps of Bonney and Nichols: hysterectomy during surgical repair of pelvic organ prolapse

Images in Urogynecology

Pessary migration into the bladder: a rare episode of removal and repair of a vesicovaginal fistula

Review Article

Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review